Moreover, it was demonstrated that optimal levels of CD44 were necessary on GBM cells to generate highly infiltrative tumors in a mouse model (76, 77) and that treatment with an anti-CD44 monoclonal antibody inhibited tumor growth of local glioma in a mouse model (78). This evidence concerns the gene CD44 and central nervous system cancer.